Fundraising FoxFlagship Ventures
Venture capitalCambridge · 3 people tracked
Also known as Flagship Capital Management Inc
Find your way into Flagship Ventures
Each arrow is one introduction. Sign up to fill in the first one.
Ask Phil Wickham to introduce you to Nicholas Gorman
You →Phil · together at Flagship Ventures →Nicholas
Ask Jamie Chen to introduce you to Noubar B. Afeyan, Ph.D.
You →Jamie · together at Flagship Ventures →Noubar
Ask Sam Okafor to introduce you to Thomas Hargis
You →Sam · together at Flagship Ventures →Thomas
Sign up to find every way you can get introduced to Flagship Ventures
- Your email: who you already know at Flagship Ventures, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Flagship Ventures team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Fund manager profile
Flagship Ventures is a venture fund manager based in Cambridge. SEC filings show 2 venture funds on record, most recently Flagship Ventures Opportunities Fund I, L.P. ($350M offering) filed June 2016.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 3 people
from public directoriesFounder mafia
3 people who came through Flagship Ventures went on to found or lead other companies.
What they invest in
from 10 of 11 portfolio companiesBiotech ×7Healthtech ×3Medical Devices ×3Deep Tech ×2AI & Machine Learning ×1Consumer ×1Cybersecurity ×1Digital Health ×1
HQs:United States×8Singapore×1
Investments · 11 tracked
founders shown can be your intro pathBy year:2024 · 12022 · 12020 · 12016 · 12015 · 12013 · 12010 · 17 dated
Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
BiotechHealthtechMedical Devices
Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)Craig B. Thompson, M.D.(Founder)Brian Goff(Chief Executive Officer)in
Co-investorsARCH Venture PartnersThird Rock VenturesSamsara BioCapital
Denali Therapeutics develops therapeutics for neurodegenerative diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Marc Tessier-Lavigne(Director)inRyan Watts(Executive Officer, Director)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSteve E. Krognes(Director)in
Co-investorsARCH Venture PartnersEcoR1 CapitalF-Prime CapitalForesite CapitalGV (Google Ventures)Flagship Pioneering
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.
BiotechDeep TechMedical DevicesCambridge, US
Feng Zhang(Scientific Founder, Core Member, Broad Institute of MIT and Harvard)inGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in
Co-investorsEcoR1 CapitalGV (Google Ventures)Sofinnova VenturesAtlas VentureDeerfield Management CompanyPolaris Partners
Joule is a lightweight fitness tracker (about 1.5 grams) that attaches behind existing post-style earrings to measure heart rate, calories, and daily activity, syncing to a companion phone app over Bluetooth.
ConsumerHardwareWellness & Fitness
Co-investorsWaterloo Accelerator Centre
BiotechCambridge, US
Torben Straight Nissen(Executive Officer, Director)inJoanne Protano(Executive Officer)inDavid Epstein(Director)Harvey F. Lodish(Director)Michael Rosenblatt(Director)Roger Pomerantz(Director)in
Co-investorsFlagship PioneeringKendall Capital Partners
Seventh Sense develops face-based biometric authentication solutions that verify identity without storing facial data, serving organizations and individuals needing secure access control, document signing, and identity verification.
AI & Machine LearningCybersecurityDeep TechDigital HealthSingapore, SG
Ashish KushwahaSam TsuiVarun Chatterji
Co-investors500 GlobalFlagship PioneeringNewpath Partners
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Cambridge, US
Nancy Simonian(CEO)
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
HealthtechLexington, US
Michael Cima, Ph.D.(Director)Rahul Dhanda(Senior Vice President, Corporate Development)inJohn McDonough(Chief Executive Officer)inTom Lowery, Ph.D.(Chief Scientific Officer)Michael Gibbs, Esq.(Vice President and General Counsel)Joanne Spadoro, Ph.D.(Chief Operating Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersArcus VenturesFlybridge Capital PartnersJohnson & Johnson Innovation – JJDCPolaris Partners+1 more
Tetraphase Pharmaceuticals was a Watertown, MA biopharmaceutical company developing novel tetracycline antibiotics, including its lead drug Xerava (eravacycline) for multidrug-resistant bacterial infections.
BiotechWatertown, US
Guy Macdonald(Director)inLarry Edwards(Executive Officer, Director)inMaria Stahl(Executive Officer)inChristopher Watt(Executive Officer)
BoardL. Patrick Gage(Director)Keith Maher(Director)
Co-investorsBay City CapitalF-Prime CapitalExcel Venture ManagementMediphase Venture Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 5
4 IPOs · 1 acquisitions · showing 4Agios PharmaceuticalsNASDAQ: AGIODenali TherapeuticsNASDAQ: DNLIEditas MedicineNASDAQ: EDITTetraphase Pharmaceuticalsacq. by La Jolla Pharmaceutical Company
Fund performance · per public LP disclosures · 2
as of Dec 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Flagship Pioneering – Origination Fund VII, L.P.LPs: Texas Municipal Retirement System, Michigan Municipal Employees' Retirement System | — | — | 12.6% | 1.33x | 0.00x |
| Flagship Pioneering Fund VIII, L.P.LPs: Michigan Municipal Employees' Retirement System, Texas Municipal Retirement System | — | — | 18.1% | 1.17x | 0.00x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Denali Therapeutics | 10.1% | $18.00 | Dec 2017 | $160.5M |
| Editas Medicine | 13.9% | $16.00 | Feb 2016 | $79.3M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Flagship Ventures made?
- Flagship Ventures has 11 tracked investments, 5 of which have exited.
- Where is Flagship Ventures located?
- Flagship Ventures is headquartered in Cambridge, US.